216 related articles for article (PubMed ID: 22425607)
21. Assessing the impact of CMF-like/Anthracycline-based/Anthracycline-Taxane-based/dose-dense chemotherapy in dependency of positive axillary lymph nodes/hormone receptor-status/grading/T-stage on survival - A retrospective multi-centre cohort study of 3677 patients receiving adjuvant chemotherapy.
Schwentner L; Wöckel A; König J; Janni W; Blettner M; Kreienberg R; Van Ewijk R;
Eur J Cancer; 2014 Nov; 50(17):2905-15. PubMed ID: 25239681
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant dose-dense chemotherapy for locally advanced breast cancer: a meta-analysis of published studies.
Petrelli F; Coinu A; Lonati V; Cabiddu M; Ghilardi M; Borgonovo K; Barni S
Anticancer Drugs; 2016 Aug; 27(7):702-8. PubMed ID: 27058707
[TBL] [Abstract][Full Text] [Related]
23. Anthracycline versus nonanthracycline adjuvant therapy for early breast cancer: A systematic review and meta-analysis.
Ding W; Li Z; Wang C; Dai J; Ruan G; Tu C
Medicine (Baltimore); 2018 Oct; 97(42):e12908. PubMed ID: 30335021
[TBL] [Abstract][Full Text] [Related]
24. Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer.
Farolfi A; Scarpi E; Rocca A; Mangia A; Biglia N; Gianni L; Tienghi A; Valerio MR; Gasparini G; Amaducci L; Faedi M; Baldini E; Rubagotti A; Maltoni R; Paradiso A; Amadori D
Eur J Cancer; 2015 Sep; 51(14):1874-81. PubMed ID: 26206258
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant chemotherapy in early breast cancer.
Ejlertsen B
Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
[TBL] [Abstract][Full Text] [Related]
26. Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy.
Gluz O; Mengele K; Schmitt M; Kates R; Diallo-Danebrock R; Neff F; Royer HD; Eckstein N; Mohrmann S; Ting E; Kiechle M; Poremba C; Nitz U; Harbeck N
J Clin Oncol; 2009 Dec; 27(36):6144-51. PubMed ID: 19901122
[TBL] [Abstract][Full Text] [Related]
27. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.
Mocellin S; Pasquali S; Rossi CR; Nitti D
J Natl Cancer Inst; 2010 Apr; 102(7):493-501. PubMed ID: 20179267
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Cardiotoxicity of Liposomal Doxorubicin-Based Chemotherapy in Advanced Breast Cancer: A Meta-Analysis of Ten Randomized Controlled Trials.
Xing M; Yan F; Yu S; Shen P
PLoS One; 2015; 10(7):e0133569. PubMed ID: 26204517
[TBL] [Abstract][Full Text] [Related]
29. Dose-dense chemotherapy for primary breast cancer.
Kümmel S; Rezai M; Kimmig R; Schmid P
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):75-81. PubMed ID: 17218856
[TBL] [Abstract][Full Text] [Related]
30. Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies.
Lambertini M; Ceppi M; Cognetti F; Cavazzini G; De Laurentiis M; De Placido S; Michelotti A; Bisagni G; Durando A; Valle E; Scotto T; De Censi A; Turletti A; Benasso M; Barni S; Montemurro F; Puglisi F; Levaggi A; Giraudi S; Bighin C; Bruzzi P; Del Mastro L;
Eur J Cancer; 2017 Jan; 71():34-42. PubMed ID: 27951450
[TBL] [Abstract][Full Text] [Related]
31. Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials.
Natori A; Ethier JL; Amir E; Cescon DW
Eur J Cancer; 2017 May; 77():40-47. PubMed ID: 28355581
[TBL] [Abstract][Full Text] [Related]
32. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
Martín M; Ruiz A; Ruiz Borrego M; Barnadas A; González S; Calvo L; Margelí Vila M; Antón A; Rodríguez-Lescure A; Seguí-Palmer MA; Muñoz-Mateu M; Dorca Ribugent J; López-Vega JM; Jara C; Espinosa E; Mendiola Fernández C; Andrés R; Ribelles N; Plazaola A; Sánchez-Rovira P; Salvador Bofill J; Crespo C; Carabantes FJ; Servitja S; Chacón JI; Rodríguez CA; Hernando B; Álvarez I; Carrasco E; Lluch A
J Clin Oncol; 2013 Jul; 31(20):2593-9. PubMed ID: 23733779
[TBL] [Abstract][Full Text] [Related]
33. Dose variation and regimen modification of adjuvant chemotherapy in daily practice affect survival of stage I-II and operable stage III Taiwanese breast cancer patients.
Kuo SH; Lien HC; You SL; Lu YS; Lin CH; Chen TZ; Huang CS
Breast; 2008 Dec; 17(6):646-53. PubMed ID: 18595699
[TBL] [Abstract][Full Text] [Related]
34. Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: a meta-analysis of phase III randomized control trials.
Shao N; Wang S; Yao C; Xu X; Zhang Y; Zhang Y; Lin Y
Breast; 2012 Jun; 21(3):389-93. PubMed ID: 22542064
[TBL] [Abstract][Full Text] [Related]
35. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.
; Basser RL; O'Neill A; Martinelli G; Green MD; Peccatori F; Cinieri S; Coates AS; Gelber RD; Aebi S; Castiglione-Gertsch M; Viale G; Price KN; Goldhirsch A
J Clin Oncol; 2006 Jan; 24(3):370-8. PubMed ID: 16421418
[TBL] [Abstract][Full Text] [Related]
36. A comparison of the outcomes of non-randomised chemotherapy regimens in node positive breast cancer.
Kuru B; Camlibel M; Dinc S; Gulcelik MA; Atalay C; Alagol H
J Exp Clin Cancer Res; 2005 Sep; 24(3):363-72. PubMed ID: 16270522
[TBL] [Abstract][Full Text] [Related]
37. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
39. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
Fisher B; Jeong JH; Anderson S; Wolmark N
J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638
[TBL] [Abstract][Full Text] [Related]
40. SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.
Budd GT; Barlow WE; Moore HC; Hobday TJ; Stewart JA; Isaacs C; Salim M; Cho JK; Rinn KJ; Albain KS; Chew HK; Burton GV; Moore TD; Srkalovic G; McGregor BA; Flaherty LE; Livingston RB; Lew DL; Gralow JR; Hortobagyi GN
J Clin Oncol; 2015 Jan; 33(1):58-64. PubMed ID: 25422488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
